Skip to main content
Premium Trial:

Request an Annual Quote

Steve Chapman, Robert Schueren, Matthew Rabinowitz

Natera has appointed Steve Chapman to CEO. He will take over from Matthew Rabinowitz, who will serve as executive chairman, effective Jan. 2, 2019. Chapman was previously the company's chief operating officer and Robert Schueren will replace Chapman as Natera's COO, effective Jan. 7, 2019. Schueren was most recently CEO of IntegenX, which was acquired by Thermo Fisher Scientific. Previously, he was general manager of genomics at Agilent Technologies and has also held various roles at Genentech.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.